GlassScriptPhysician profile
Smitha K Holla
NPI 1922386929
$985.37
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $413.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $150.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $135.42 | 2019 | |
| Biogen, INC. | $78.36 | 2019 | |
| Emd Serono, INC. | $41.52 | 2019 | |
| Allergan, INC. | $36.69 | 2019 | |
| Acorda Therapeutics, INC | $22.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.52 | 2019 | |
| Pfizer INC. | $17.13 | 2019 | |
| Acadia Pharmaceuticals INC | $15.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.81 | 2019 | |
| Celgene Corporation | $15.65 | 2019 | |
| Lilly USA, LLC | $12.98 | 2019 | |
| Genentech USA, INC. | $11.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Holla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.